Trevi Therapeutics’ Jennifer Good, Biohaven Pharmaceuticals’s Vlad Coric Win 2017 CURE Entrepreneur of the Year Awards
In a ceremony December 12 at the CURE Annual Holiday Party at Alexion in New Haven, the 2017 CURE Entrepreneur of the Year award was presented to Jennifer Good of Trevi Therapeutics and Dr. Vlad Coric of Biohaven Pharmaceuticals, two biotechnology executives whose work has positively affected bioscience in Connecticut and beyond.
The Entrepreneur of the Year award was established by CURE and the law firm of Shipman & Goodwin to acknowledge the importance of showcasing unique accomplishments of entrepreneurs in the Connecticut community.
Dormer Stephen, a partner at Shipman & Goodwin, said, “Both Jennifer Good and Dr. Coric’s accomplishments and contributions within the Connecticut bioscience community are a great fit for the 2017 CURE Entrepreneur of the Year award, and we are proud to recognize each of them for their hard work and dedication.”
Jennifer Good is the co-founder of Trevi Therapeutics, Inc. and serves as a director as well as the Company’s President and Chief Executive Officer. Ms. Good has served as the Company’s President and CEO since inception, raising through Series C capital and overseeing the development of Nalbuphine ER into Phase 3 development. Prior to founding Trevi, Ms. Good successfully led the transition of a publicly traded life sciences company, Penwest Pharmaceuticals Co., from a development stage company to generating annual revenues in excess of $50 million with strong profitability. The Company was acquired by its strategic partner in 2010.
Ms. Good received a Bachelor of Business Administration degree with a Concentration in Accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Ms. Good currently serves on the board of Juniper Pharmaceuticals, a publicly traded women’s health therapeutics company, and is a member of Juniper’s Audit and Compensation Committees. In addition, Ms. Good is a board member of the Friedreich’s Ataxia Research Alliance (FARA), which is a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia. Ms. Good serves on FARA’s Executive, Business Development and Finance Committees. Ms. Good is also the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community.
Vlad Coric, M.D. has served as the chief executive officer and director of Biohaven Pharmaceuticals, Inc. since October 2015. Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Dr. Coric has helped Biohaven raise over $100M since its inception, and investors include leading biotech funds such as Venrock, RA Capital Management, Vivo Capital, Aisling Capital, Rock Springs Capital, John W. Childs, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations, Greg Bailey and Litmore Capital.
Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma. He has been involved in multiple drug development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), YERVOY® (Ipilimumab; anti-CTLA-4), DAKLINZA® (daclatasvir; NS5A inhibitor) and SUNVEPRA® (asunaprevir; NS3 inhibitor). He has conducted numerous clinical trials in various illnesses including obsessive compulsive disorder, generalized anxiety disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, hepatocellular carcinoma, and glioblastoma. Dr. Coric was the first to report the therapeutic effects of the glutamate-modulating agent riluzole in neuropsychiatric disorders (Coric et al., 2003; 2005; Sanacora et al., 2004) and led the first clinical trial employing cerebrospinal fluid biomarkers to identity and enrich for patients with Prodromal Alzheimer’s Disease while at Bristol-Myers Squibb (Coric et al 2015). Additionally, Dr. Coric spearheaded the design of and led the first global registrational trial using checkpoint inhibitors in glioblastoma. Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as President of the Connecticut Psychiatric Society (an 800 member district branch of the American Psychiatric Association). Dr. Coric completed residency training at the Yale Psychiatry Residency Training Program, where he also served as the Program-Wide Chief Resident for the Yale Department of Psychiatry, and Chief Resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.